Though development dynamics of russian pharmaceutical market does not fully follow crisis processes, it still leaves much to be desired. This is especially noticeable on the background of indicators which the market has showed over the preceding years. The relatively modest market growth in terms of value is accompanied by a rather noticeable reduction of its real volume. A situation like this, for classical wholesalers is generally beneficial, as the average cost of the processed product package is increasing, while operating costs are reducing. Perhaps because of this, the investment activity in the field of wholesale trade remains on a relatively high level, which is a rather uncharacteristic phenomenon during the crisis. However, the majority of wholesalers have to grow at the expense of internal resources, as external financing in the first half of 2014 was possible only in a few companies.

In general, distributors development goes both ways: diversification of the main business, in particular, at the expense of investment to the production segment ("R-Pharm") or the development of its own retail chain ("Protek", "growth" and others.) and further markets expansion - wholesalers actively explore new geographic markets, including Republic of Crimea.